We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Role of Sulfotransferases in Drug Metabolism and Potential for Drug Drug Interactions

Presenter: Maciej Czerwinski, Ph.D., SEKISUI XenoTech Director of Scientific Consulting

Continuing our series on non-CYP-mediated metabolism pathways, we will be discussing another of the most requested enzymes: Sulfotransferases (SULTs). SULTs participate in Phase 2 metabolism of xenobiotics in humans and are characterized by the abundance and broad tissue distribution of the enzymes. Gene regulation and genetic polymorphism of SULTs also contribute to our understanding of the significance of these enzymes in the process of drug development. Basic biochemical characteristics of SULTs will be reviewed and examples of major forms of sulfonates formed in humans will be presented. Some properties of SULTs-mediated metabolism will be compared to other major Phase 2 enzymes, particularly UDP-glucuronosyltransferases (UGTs).

Key concepts discussed in this webinar will include:
- Significance of SULT-mediated metabolism in the drug development process
- Tissue distribution of human SULTs
- Gene regulation of SULT enzymes

Download a copy of the slides: https://www.xenotech.com/about/events/role-of-sulfotransferases-in-drug-metabolism-and-potential-for-drug-drug-interactions/

Questions, comments and requests: https://www.xenotech.com/contact-us

More information on our research services and test systems: https://www.xenotech.com

Other previously aired webinars: https://www.xenotech.com/scientific-resources/webinar-series

Upcoming webinar notifications: https://www.xenotech.com/newsletter-signup

Request a webinar topic: https://www.xenotech.com/scientific-


About the Presenter:
Dr. Maciej Czerwinski serves as a Director in the Scientific Consulting department at SEKISUI XenoTech. He received his Ph.D. from the University of Maryland at Baltimore Medical School in the Department of Pathology. Dr. Czerwinksi conducted his doctoral thesis research in the Laboratory of Dr. Frank Gonzalez at the National Cancer Institute in Bethesda, followed by a post-doc at the Department of Pharmaceutics, the University of Washington in Seattle. He has been with SEKISUI XenoTech since 1999 and guides the development of products and services for the in vitro analysis of drug safety. Dr. Czerwinski designed a patented method to analyze the in vitro cytokine-mediated drug-drug interactions between biologics and small molecule drugs, and he is also the inventor of SEKISUI XenoTech’s CryostaX single-freeze pooled hepatocytes.